Summary & Overview
HCPCS J7312: Dexamethasone Intravitreal Implant, 0.1 mg
HCPCS Level II code J7312 denotes a dexamethasone intravitreal implant, 0.1 mg, administered via injection into the vitreous cavity. This ophthalmic drug delivery modality is important for targeted intraocular corticosteroid therapy and has implications for specialty drug billing, site-of-service policies, and coverage determinations across national payers. The code is used to identify the specific drug product and dose for claims processing and utilization monitoring.
Key payers covered in this analysis include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a concise overview of clinical context for intravitreal dexamethasone implants, payer coverage patterns and coding considerations, common modifiers applicable to drug and procedure billing, and benchmarks where available. The publication also highlights policy items that affect reimbursement and prior authorization practices for intravitreal corticosteroid implants.
This summary provides clinicians, billing professionals, and policy analysts with the essentials needed to recognize when J7312 applies, how site-of-service influences claim submission, and what to expect from major national payers. Data not available in the input will be noted in the relevant sections of the full publication.
Billing Code Overview
HCPCS Level II code J7312 describes an injection, dexamethasone, intravitreal implant, 0.1 mg. The service is an intravitreal pharmacologic implant intended for ophthalmic use, delivered via injection into the vitreous cavity of the eye.
Service Type: Intravitreal implant injection
Typical Site of Service: Inpatient or outpatient ophthalmology settings, including ambulatory surgery centers and specialty clinics that provide intravitreal procedures
Clinical & Coding Specifications
Clinical Context
A typical patient is an adult with persistent macular edema due to diabetic retinopathy or retinal vein occlusion or noninfectious posterior uveitis who has inadequate response to topical therapy or prior intravitreal anti-VEGF injections. The patient arrives at an ophthalmology clinic or ambulatory surgical center for a scheduled intravitreal procedure. Pre-procedure workflow includes history review, informed consent, medication reconciliation, topical anesthesia and povidone-iodine antisepsis, and measurement of intraocular pressure as indicated. The service involves implantation of a sustained-release intravitreal dexamethasone implant (J7312, 0.1 mg) into the vitreous cavity under sterile technique. Post-procedure workflow includes monitoring for immediate complications, discharge instructions addressing signs of infection, elevated intraocular pressure, and follow-up scheduling for intraocular pressure checks and visual acuity assessment.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|
00 | Unspecified | Use only if payer requires a default unspecified modifier; rarely applied clinically |
11 |